Gatto, M., Zen, M., Cruciani, C., Iaccarino, L. & Doria, A. Navigating the landscape of SLE treatment: an expert viewpoint on the rationality and limitations of early biologic intervention. Autoimmun. Rev. 23, 103612 (2024).
Gumkowska-Sroka, O., Kotyla, K., Mojs, E., Palka, K. & Kotyla, P. Novel therapeutic strategies in the treatment of systemic sclerosis. Pharmaceuticals 16, 1066 (2023).
Cooper, N. & Ghanima, W. Immune thrombocytopenia. N. Engl. J. Med. 381, 945–955 (2019).
Stockfelt, M., Teng, Y. K. O. & Vital, E. M. Opportunities and limitations of B cell depletion approaches in SLE. Nat. Rev. Rheumatol. 21, 111–126 (2025).
van Dam, L. S. et al. Highly sensitive flow cytometric detection of residual B-cells after rituximab in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients. Front. Immunol. 11, 566732 (2020).
Mahevas, M. et al. Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. J Autoimmun. 62, 22–30 (2015).
Canales-Herrerias, P. et al. High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura. J. Clin. Invest. 132, e153580 (2022).
Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149–1155 (2020).
Jalink, M. et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 8, 2622–2634 (2024).
Strussmann, T. et al. Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab. Ann. Hematol. 102, 245–247 (2023).
Vernava, I. & Schmitt, C. A. Daratumumab as a novel treatment option in refractory ITP. Blood Cells Mol. Dis. 99, 102724 (2023).
Giammarco, S. et al. The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA. Bone Marrow Transplant. 60, 305–309 (2025).
Chen, Y. et al. A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia. N. Engl. J. Med. 390, 2178–2190 (2024).
Sun, T., Chen, Y. & Zhang, L. Daratumumab in relapsed or refractory pediatric immune thrombocytopenia. N. Engl. J. Med. 392, 2069–2071 (2025).
Holzer, M. T. et al. Daratumumab for autoimmune diseases: a systematic review. RMD Open 9, e003604 (2023).
Otani, I. M. et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J. Allergy Clin. Immunol. 149, 1525–1560 (2022).
Hooftman, A. et al. Macrophage fumarate hydratase restrains mtRNA-mediated interferon production. Nature 615, 490–498 (2023).
Ziegler, J. F. et al. Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and combined Crohn’s disease. Nat. Commun. 10, 5629 (2019).
Zheng, X., Tsou, P. S. & Sawalha, A. H. Increased expression of EZH2 is mediated by higher glycolysis and mTORC1 activation in lupus CD4+ T cells. Immunometabolism 2, e200013 (2020).
Wei, J. et al. Elevated fatty acid β-oxidation by leptin contributes to the proinflammatory characteristics of fibroblast-like synoviocytes from RA patients via LKB1-AMPK pathway. Cell Death Dis. 14, 97 (2023).
Legroux, T. M. et al. Immunomodulation by glucocorticoid-induced leucine zipper in macrophages: enhanced phagocytosis, protection from pyroptosis, and altered mitochondrial function. Front. Immunol. 15, 1396827 (2024).
Li, X. et al. Excess glucocorticoids inhibit murine bone turnover via modulating the immunometabolism of the skeletal microenvironment. J. Clin. Invest. 134, e166795 (2024).
Gan, P. X. L., Liao, W., Lim, H. F. & Wong, W. S. F. Dexamethasone protects against Aspergillus fumigatus-induced severe asthma via modulating pulmonary immunometabolism. Pharmacol. Res. 196, 106929 (2023).
Auger, J. P. et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature 629, 184–192 (2024).
Jenkins, B. J. et al. Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. Cell Metab. 35, 1132–1146 (2023).
Montano, E. N. et al. α-Ketoglutarate−dependent KDM6 histone demethylases and interferon-stimulated gene expression in lupus. Arthritis Rheumatol. 76, 396–410 (2024).
Pan, W., Tsokos, M. G., Scherlinger, M., Li, W. & Tsokos, G. C. The PP2A regulatory subunit PPP2R2A controls NAD+ biosynthesis to regulate T cell subset differentiation in systemic autoimmunity. Cell Rep. 43, 114379 (2024).
Masuyama, S. et al. Enhanced fatty acid oxidation by selective activation of PPARα alleviates autoimmunity through metabolic transformation in T-cells. Clin. Immunol. 268, 110357 (2024).
Angiari, S. et al. Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity in experimental neuroinflammation. J. Neuroinflammation 21, 287 (2024).
Jia, N. et al. Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms. Signal Transduct. Target. Ther. 8, 280 (2023).
Meyer, T. et al. NAD+ metabolism drives astrocyte proinflammatory reprogramming in central nervous system autoimmunity. Proc. Natl Acad. Sci. USA 119, e2211310119 (2022).
Gil Alabarse, P., Chen, L. Y., Oliveira, P., Qin, H. & Liu-Bryan, R. Targeting CD38 to suppress osteoarthritis development and associated pain after joint injury in mice. Arthritis Rheumatol. 75, 364–374 (2023).
Covarrubias, A. J., Perrone, R., Grozio, A. & Verdin, E. NAD+ metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 22, 119–141 (2021).
Minhas, P. S. et al. Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation. Nat. Immunol. 20, 50–63 (2019).
Feng, Q. et al. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia. J. Thromb. Haemost. 15, 1845–1858 (2017).
Liang, Z. et al. Mesenchymal stromal cells regulate M1/M2 macrophage polarization in mice with immune thrombocytopenia. Stem Cells Dev. 32, 703–714 (2023).
Zhao, H. Y. et al. M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. Signal Transduct. Target. Ther. 6, 234 (2021).
Kasperczyk, H. et al. Betulinic acid as new activator of NF-κB: molecular mechanisms and implications for cancer therapy. Oncogene 24, 6945–6956 (2005).
Tien, T. Y. et al. Reduction of connexin 43 attenuates angiogenic effects of human smooth muscle progenitor cells via inactivation of Akt and NF-κB pathway. Arterioscler. Thromb. Vasc. Biol. 41, 915–930 (2021).
Hoffmann, A., Cheng, G. & Baltimore, D. NF-κB: master regulator of cellular responses in health and disease. Immun. Inflamm. 1, 2 (2025).
Liu, J., Chen, Y. & O’ Neill, L. Phospholipid metabolism in innate immunity and inflammation: from basic to clinic. Immun. Inflamm. 1, 6 (2025).
Irie, J. et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr. J. 67, 153–160 (2020).
Mitchell, S. J. et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. Cell Metab. 27, 667–676 (2018).
Yoshino, M. et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 372, 1224–1229 (2021).
Malique, A. et al. NAD+ precursors and bile acid sequestration treat preclinical refractory environmental enteric dysfunction. Sci. Transl. Med. 16, eabq4145 (2024).
Jablonski, K. A. et al. Novel markers to delineate murine M1 and M2 macrophages. PLoS ONE 10, e0145342 (2015).
Wen, S., Arakawa, H. & Tamai, I. CD38 activation by monosodium urate crystals contributes to inflammatory responses in human and murine macrophages. Biochem. Biophys. Res. Commun. 581, 6–11 (2021).
Lory, W. et al. CD38 inhibitor 78c attenuates pro-inflammatory cytokine expression and osteoclastogenesis in macrophages. Cells 13, 1971 (2024).
Ma, Y. et al. Deletion of CD38 mitigates the severity of NEC in experimental settings by modulating macrophage-mediated inflammation. Redox Biol. 77, 103336 (2024).
Bussel, J. B. et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 77, 1884–1893 (1991).
Khellaf, M. et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 124, 3228–3236 (2014).
Bennett, C. M. et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107, 2639–2642 (2006).
Mann, R., Stavrou, V. & Dimeloe, S. NAD + metabolism AND function in innate AND adaptive immune cells. J. Inflamm. 22, 30 (2025).
Navarro, M. N., Gómez de Las Heras, M. M. & Mittelbrunn, M. Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing. Br. J. Pharmacol. 179, 1839–1856 (2022).
Li, J. et al. Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia. Br. J. Haematol. 205, 2432–2441 (2024).
Jing, C. et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc. Natl Acad. Sci. USA 117, 15160–15171 (2020).
Cuda, C. M., Pope, R. M. & Perlman, H. The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases. Nat. Rev. Rheumatol. 12, 543–558 (2016).
Neunert, C. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 3, 3829–3866 (2019).
Katsman, Y., Foo, A. H., Leontyev, D. & Branch, D. R. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Transfusion 50, 1285–1294 (2010).
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 (2019).
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086 (2017).
Buscher, K. et al. Natural variation of macrophage activation as disease-relevant phenotype predictive of inflammation and cancer survival. Nat. Commun. 8, 16041 (2017).
He, L. et al. Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. Cell Rep. 37, 109955 (2021).